שולי רווח נקי OncoCyte Inc (OCX)

OncoCyte Corp. - לוגו גרפי של המנפיק OCX

High capacity utilization of diagnostic centers and equipment modernization ensure a steady flow of tests for OncoCyte Corporation (OCX). Growth scales through the sale of Determa kit licenses, eliminating the costs associated with new laboratories. The integration of these tests into clinical practice drives the trend reflected in the net profit margin chart, where the value -1516.10 represents the issuer's current profit-to-revenue ratio.

OncoCyte Corporation (OCX) - רווחיות מכירות לפי רווח נקי מ-04.07.2022 עד 18.06.2025

פילוחים אנליטיים ודוחות נתונים של חברת OncoCyte Corporation (OCX)

- שווי שוק ותחזית יעד של אנליסטים:
ניתוח מקיף של החברה:OncoCyte Corporation, OCX
סחורת הדגל של OncoCyte Inc

Determa high-precision molecular tests determine the commercial effectiveness of OncoCyte Corporation (OCX) in lung cancer diagnostics. This net profit margin metric measures the portion of net income in every dollar of revenue, reflecting the ultimate efficiency of the operating model. Analyzing this trend helps avoid freezing capital in overheated assets during a cycle shift. The investor sees the business's real ability to generate income without quarterly delays. This net profit margin chart reveals hidden drawdown risks.